McKesson Applauds DOJ Policy Change on Opioid Quotas
Summary
SAN FRANCISCO--(BUSINESS WIRE)--McKesson Corporation today praised the U.S. Department of Justice’s decision to exercise its authority to reduce opioid production if the agency believes a particular drug is highly diverted. The annual opioid production quota determines the total amount of controlled substances that can be produced each year. That authority is significant as the nation struggles to address the current public health crisis around opioid addiction. McKesson is deeply concerned by the impact the opioid epidemic is having on families and communities across the nation—and is committed to being part of the solution. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful — all for the better health of patients.
Classifications
AskAI Classifications
LabelsLinked Companies
